Synthetic lethality may help overcome cancer therapeutic resistance by exploiting tumour vulnerabilities, supported by ...

TROPION-Lung17 will enroll approximately 400 patients across global sites. Participants are randomized 1:1 to receive either ...

Ipsen (IPSEY) stock rises after the FDA offered Breakthrough Therapy Designation for its antibody therapy IPN60340 in acute myeloid leukemia. Read more here.

The only potentially curative options for gastric cancer involve endoscopic or surgical resection, with adjunctive systemic ...

Zoldonrasib targets KRAS G12D-mutated non-small cell lung cancer, receiving FDA breakthrough therapy designation for its ...

Breakthrough Therapy Designation granted to zoldonrasib for the treatment of adult patients with KRAS G12D-mutated locally ...

Explore the potential of polysaccharide microneedles in cancer immunotherapy for effective drug delivery and immune ...

Durable complete responses with CAR-NK + Rituximab in patients who failed current standards of care in Waldenstrom’s ...

Patients should be selected for treatment with Enhertu in combination with pertuzumab based on confirmed HER2-positive status or HER2 gene amplification (IHC 3+ or ISH+).

Cancer represents a key challenge in medical science, manifesting as a disease where the immune system fails to recognize and eliminate tumor cells. The phenomenon of immune evasion by cancer cells ...

HIGHLIGHTSFollowing an interim data review of the Cohort Expansion Phase (Phase II) of the SECuRE trial, the Safety Review ...

Common diabetes drugs may do more than regulate blood sugar—they could also influence how cancers grow, spread, or slow down. Researchers are now unraveling how these medications affect immune ...